Keith W. Marshall - Dec 16, 2022 Form 4 Insider Report for Prometheus Biosciences, Inc. (RXDX)

Role
Chief Financial Officer
Signature
/s/ Timothy K. Andrews, attorney-in-fact for Keith W. Marshall
Stock symbol
RXDX
Transactions as of
Dec 16, 2022
Transactions value $
$0
Form type
4
Date filed
12/20/2022, 07:19 PM
Previous filing
Dec 13, 2022
Next filing
Jan 19, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXDX Stock Option (Right to Buy) Award $0 +12.9K $0.00 12.9K Dec 16, 2022 Common Stock 12.9K $108.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option will vest on December 16, 2023, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.